This is a transformative clinical data readout for a pre-revenue biotech. The 100% ORR and 18.2-month OS substantially exceed historical benchmarks, and the FDA discussion for a larger U.S. study adds a clear near-term catalyst. Expect significant upside momentum; monitor for any equity offering to fund the larger trial.
Price Chart
Executive Summary
Alpha Tau reported positive clinical data from a study of Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). The combination produced a 100% objective response rate (ORR) and a median overall survival of 18.2 months among evaluable patients, significantly exceeding historical benchmarks for pembrolizumab monotherapy (19% ORR, 12.3 months OS). The trial met its pre-specified success criterion, and the company is discussing a larger U.S. study with the FDA, representing a major pipeline catalyst for this pre-revenue oncology company.
Key Facts
- Alpha DaRT plus pembrolizumab produced a 100% objective response rate (ORR) in 9 evaluable patients with HNSCC, vs. ~19% historical benchmark for pembrolizumab monotherapy.
- Median overall survival was 18.2 months, vs. 12.3 months for pembrolizumab monotherapy in KEYNOTE-048.
- Median progression-free survival was 5.4 months, vs. 3.2 months for pembrolizumab monotherapy.
- No Alpha DaRT-related serious adverse events were observed; only two Grade 1 adverse events were reported.
- The trial met its pre-specified success criterion (more than six patients responding), and enrollment was concluded.
- Company is in ongoing discussions with the FDA regarding a larger U.S. study of the combination.
Financial Impact
No financial figures reported; company is pre-revenue. The positive data is a significant pipeline catalyst that could accelerate regulatory pathway and partnership potential.
Risk Factors
- Small sample size (9 evaluable patients) — results may not replicate in larger, controlled studies.
- Single-center, open-label, single-arm design limits comparability to standard of care.
- Company is pre-revenue and will require additional capital to fund larger trials and potential commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079822 |
| Document: ea0298609-6k_alpha.htm | 0001213900-26-079822 |
| Document: 0001213900-26-079822-index-headers.html | 0001213900-26-079822 |
| Document: 0001213900-26-079822-index.html | 0001213900-26-079822 |
| Document: 0001213900-26-079822.txt | 0001213900-26-079822 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access